Anika Therapeutics (ANIK) Receivables (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Receivables data on file, last reported at $26.9 million in Q1 2026.

• Receivables for Q1 2026 came in at $26.9 million, up 22.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.9 million (up 22.16% YoY), and the FY2025 annual result was $23.7 million, changed 0.41% from the prior year.
• Receivables grew to $26.9 million in Q1 2026 per ANIK's latest filing, from $23.7 million in the prior quarter.
• Over five years, Receivables peaked at $38.4 million in Q2 2023 and troughed at $22.0 million in Q1 2025.
• A 5-year average of $29.1 million and a median of $27.6 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2025 and 2026: Receivables tumbled 34.82% in 2025, then advanced 22.16% in 2026.
• A 5-year view of Receivables shows it stood at $34.6 million in 2022, then retreated by 23.87% to $26.4 million in 2023, then fell by 10.49% to $23.6 million in 2024, then advanced by 0.41% to $23.7 million in 2025, then grew by 13.38% to $26.9 million in 2026.
• Business Quant data shows ANIK's Receivables at $26.9 million in Q1 2026, $23.7 million in Q4 2025, and $23.1 million in Q3 2025.